Hemactiv Indications/Uses

Indicated for the Treatment of symptomatic anemia associated with chronic renal failure (CRF): in adults and pediatrics aged 1 to 18 years on hemodialysis and adult patients on peritoneal dialysis; in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anemia of renal origin accompanied by clinical symptoms in patients.
Indicated for the treatment of anemia and reduction of transfusion requirements: In adults receiving chemotherapy for solid tumors, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anemia at the start of chemotherapy).
Indicated in adults in a predonation programme to increase the yield of autologous blood: Treatment should only be given to patients with moderate anemia (hemoglobin concentration range between 10 to 13g/dL [6.2 to 8.1 mmol/L], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Indicated for non-iron deficient adults prior to major elective orthopedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions: Use should be restricted to patients with moderate anemia (e.g. hemoglobin concentration range between 10 to13 g/dL) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800 mL).